首页 | 本学科首页   官方微博 | 高级检索  
检索        

弥可葆、前列地尔和银杏达莫联合用药治疗糖尿病周围神经病变的临床研究
引用本文:汪艳茹.弥可葆、前列地尔和银杏达莫联合用药治疗糖尿病周围神经病变的临床研究[J].中国医药导报,2012,9(18):85-86,89.
作者姓名:汪艳茹
作者单位:新疆维吾尔自治区奇台县人民医院内分泌科,新疆奇台,831800
摘    要:目的探讨弥可葆、前列地尔和银杏达莫联合用药治疗糖尿病周围神经病变的临床疗效。方法选取本院2008年1月~2011年6月收治的糖尿病周围神经病变患者92例,随机分为两组。所有患者均采用相同的血糖控制方法,采用弥可葆(500μg/次,1次/d)肌内注射治疗的患者46例为对照组,采用弥可葆(500μg/次,1次/d)肌内注射、前列地尔(10μg/次,1次/d)加入100 mL生理盐水中静脉滴注、银杏达莫注射液(20 mL/次,1次/d)加入250 mL生理盐水中静脉滴注治疗的患者46例为观察组。两组患者的治疗疗程均为14 d,疗程结束后分析比较两组患者的神经传导速度和临床疗效。结果治疗后对照组患者正中神经和腓总神经的运动传导速度和感觉传导速度均明显增加,与治疗前相比较,差异均有统计学意义(P〈0.05)。治疗后观察组患者正中神经和腓总神经的运动传导速度和感觉传导速度也均明显增加,与治疗前相比较,差异均有统计学意义(P〈0.05)。治疗后观察组患者正中神经和腓总神经的运动传导速度和感觉传导速度均明显高于对照组,与治疗后对照组相比较,差异均有统计学意义(P〈0.05)。治疗后观察组患者总有效率(76.1%)明显高于对照组(52.2%),差异有统计学意义(P〈0.05)。结论采用弥可葆、前列地尔和银杏达莫联合用药治疗糖尿病周围神经病变的临床疗效显著,不仅可以有效改善糖尿病患者周围神经病变的临床症状,还可以大幅提高糖尿病患者的神经传导速度,是一种安全有效的治疗手段,值得临床推广使用。

关 键 词:弥可葆  前列地尔  银杏达莫  糖尿病  周围神经病变

Clinical research on combined use of Mecobalamin,Alprostadil and Ginkgo Dipyridolum in the treatment of diabetic peripheral neuropathy
WANG Yanru.Clinical research on combined use of Mecobalamin,Alprostadil and Ginkgo Dipyridolum in the treatment of diabetic peripheral neuropathy[J].China Medical Herald,2012,9(18):85-86,89.
Authors:WANG Yanru
Institution:WANG Yanru Department of Endocrine,the People’s Hospital of Qitai County,Xinjiang Uygur Autonomous Region,Qitai 831800,China
Abstract:Objective To investigate the clinical effect of combined use of Mecobalamin,Alprostadil and Ginkgo Dipyridolum in the treatment of diabetic peripheral neuropathy.Methods 92 patients with diabetic peripheral neuropathy were selected in the hospital from January 2008 to June 2011,who were randomly divided into two groups.All patients were treated with the same blood glucose control method.46 patients were given Mecobalamin(500 μg/time,1 time/d) intramuscular injection in the treatment as the control group.46 patients were given Mecobalamin(500 μg/time,1 time/d) intramuscular injection,Alprostadil(10 μg/time,1 time/d) joined 100 mL saline infusion,Ginkgo Dipyridolum(20 mL/time,1 time/d) joined 250 mL saline infusion in the treatment as the observation group.The treatment regimens of two groups were all 14 d.At the end of treatment nerve conduction velocity and clinical curative effect were analyzed and comparied between the two groups.Results The motor conduction velocity and sensory conduction velocity of median nerve and peroneal nerve of patients in the control group were increased significantly after the treatment.Compared with before the treatment in the control group,the differences were statistically significant(P < 0.05).The motor conduction velocity and sensory conduction velocity of median nerve and peroneal nerve of patients in the observation group were also increased significantly after the treatment.Compared with before the treatment in the observation group,the differences were statistically significant(P < 0.05).The motor conduction velocity and sensory conduction velocity of median nerve and peroneal nerve of patients in the observation group after the treatment were significantly higher than those in the control group after the treatment.Compared with after the treatment in the control group,the differences were statistically significant(P < 0.05).The total effective rate(76.1%) in the observation group after the treatment was significantly higher than the control group(52.2%),while the difference was statistically significant(P < 0.05).Conclusion Alprostadil and Mecobalamin,Ginkgo Dipyridolum combined medication in the treatment of diabetic peripheral neuropathy has a clinical curative effect,which can not only effectively improve the diabetic patients with peripheral neuropathy clinical symptoms,but also can greatly improve the nerve conduction velocity in patients with diabetes mellitus.That is a safe and effective treatment method,which is worthy of clinical use.
Keywords:Mecobalamin  Alprostadil  Ginkgo Dipyridolum  Diabetes  Peripheral neuropathy
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号